Technology
Health
Biotechnology
AnaptysBio
$74.709876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$74.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.37 (1.87%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell AnaptysBio and other stocks, options, ETFs, and crypto commission-free!
About
AnaptysBio, Inc. Common Stock, also called AnaptysBio, is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Read More Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
CEO
Employees
78
Headquarters
San Diego, California
Founded
2005
Market Cap
2.02B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
324.33K
High Today
$75.54
Low Today
$73.43
Open Price
$73.83
Volume
69.47K
52 Week High
$110.00
52 Week Low
$54.26
Collections
Technology
Health
Biotechnology
Medical
2017 IPO
US
North America
News
Yahoo FinanceMay 1
Is AnaptysBio, Inc. (ANAB) A Good Stock To Buy?
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the fourth quarter, which unveil their equity positions as of December 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions.
Price Paid on Robinhood
13% Lower
Right Now
52 Week Low
$54.26
Average Price Paid
$85.78
52 Week High
$110.00
Earnings
-$0.92
-$0.71
-$0.51
-$0.30
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 6, After Hours